Close Menu

mergers & acquisitions

The firm said it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.

JP Morgan noted that it sees potential for new management to "reset the bar" and as such thinks the "worst is in the rearview for Qiagen."

The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.

In a response to the UK CMA's findings that the PacBio deal would lessen competition, Illumina said it would be open to licensing some IP to Oxford Nanopore.

The deal includes Expedeon's core proteomics business, as well as its immunology-focused subsidiaries Innova Biosciences and TGR Biosciences.

The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.

The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.

Strong growth in instrument revenue, driven by sales of the Sequel II system, was tempered by decreased consumable revenue as customers transitioned to the new platform.

OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.

The acquisition of immunohistochemistry services provider QualTek will augment Discovery's existing histopathology services, the company said.

Pages

An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.

DNA testing confirms captured Chicago coyote same as the one that bit a boy near a nature museum, the Chicago Tribune reports.

An analysis of Tibetan ice cores uncovers more than two dozen previously unknown virus groups, LiveScience reports.

In Nature this week: genomic analysis of four children buried in Cameroon approximately 3,000 and 8,000 years ago, and more.